FCA
ALXN

FinTrust Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

FinTrust Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67
Closed -$8K – 1215
2020
Q2 		$8K Sell
67
-270
-80% -$28.7K ﹤0.01% 772
2020
Q1 		$30K Sell
337
-301
-47% -$29.5K 0.01% 541
2019
Q4 		$69K Sell
638
-3,694
-85% -$395K 0.03% 388
2019
Q3 		$424K Buy
4,332
+336
+8% +$37.9K 0.14% 137
2019
Q2 		$524K Buy
3,996
+3,549
+794% +$457K 0.21% 104
2019
Q1 		$60K Buy
+447
New +$55.6K 0.03% 356

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FinTrust Capital Advisors's ALXN Position: Q3 2020 in Review

FinTrust Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 67 shares — an estimated $8K sold.

FinTrust Capital Advisors first reported a position in ALXN in Q1 2019 and held it in 6 quarters. The position peaked at $524K in Q2 2019. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • FinTrust Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 67 Alexion Pharmaceuticals shares in Q3 2020, an estimated $8K.
  • FinTrust Capital Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 6 quarters.
  • FinTrust Capital Advisors's Alexion Pharmaceuticals position peaked at $524K in Q2 2019.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on FinTrust Capital Advisors's 13F filing for Q3 2020, filed 10 Nov 2020.